ClinicalTrials.gg
RecruitingNCT07144813NSM-005Updated Feb 4, 2026

Post-Approval Study of the Neuspera Sacral Neuromodulation System

An interventional study of Neuspera Implantable Sacral Neuromodulation System in Urinary Urgency Incontinence, sponsored by Neuspera Medical, Inc.. Recruiting at 20 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Neuspera Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

Prospective, multi-center, single-arm, post-approval study is designed to assess the long-term safety and efficacy data of the Neuspera Sacral Neuromodulation (SNM) System following commercial approval of the Neuspera SNM System.

Participants in this study received intervention/implanted in Phase I or Phase II of the Neuspera SANS_UUI (NSM-004) Study.

Read the detailed description

The Neuspera SNM System received FDA PMA approval for the treatment of urinary urge incontinence in subjects who have failed, could not tolerate, or were not a candidate for more conservative treatment. The study will serve as the Post Approval Study (PAS) requirement of the PMA Approval.

This post approval study (PAS) is designed to assess the long-term safety and effectiveness data out to 72 months post-implant, in consenting subjects implanted in Phase I or Phase II study.

02

Conditions studied

  • Urinary Urgency Incontinence

Keywords

  • UUI
03

In context

Lead sponsor

Neuspera Medical, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects in the SANS-UUI Phase I or Phase II study

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Other
    Neuspera Implantable Sacral Neuromodulation Stimulation System

    Long term follow-up for the FDA approved Neuspera Sacral Neuromodulation Stimulation system

    Device: Neuspera Implantable Sacral Neuromodulation System

Interventions

  • DeviceNeuspera Implantable Sacral Neuromodulation System

    Stimulation of the Sacral Nerve.

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint

    Incidence of device- and procedure-related AEs

    Time frame: Through 72 months

  2. Primary Effectiveness Endpoint:

    Percentage of all implanted subjects who experience an improvement in UUI episodes of at least 50% or more

    Time frame: Through 72 months

07

Study locations

1 of 20 sites recruiting
  • Kaiser Permanente Point Loma MOB
    San Diego, California 92110, United States
    Active, not recruiting

    Not enrolling at this site.

  • Genesis Healthcare Partners
    San Diego, California 92123, United States
    Active, not recruiting

    Not enrolling at this site.

  • Florida Urology Partners
    Tampa, Florida 33615, United States
    Active, not recruiting

    Not enrolling at this site.

  • Women's Health Advantage,
    Fort Wayne, Indiana 46825, United States
    Active, not recruiting

    Not enrolling at this site.

  • Indiana University, School of Medicine
    Indianapolis, Indiana 46202, United States
    Active, not recruiting

    Not enrolling at this site.

  • University of Kansas Medical Center,
    Kansas City, Kansas 66160, United States
    Active, not recruiting

    Not enrolling at this site.

  • University of Louisville Health System,
    Louisville, Kentucky 40202, United States
    Active, not recruiting

    Not enrolling at this site.

  • Ochsner Medical
    New Orleans, Louisiana 70121, United States
    Active, not recruiting

    Not enrolling at this site.

  • University of Michigan Health
    Wyoming, Michigan 49519, United States
    Active, not recruiting

    Not enrolling at this site.

  • Minnesota Urology
    Woodbury, Minnesota 55125, United States
    Active, not recruiting

    Not enrolling at this site.

  • Specialty Research of St. Louis
    St Louis, Missouri 63141, United States
    Active, not recruiting

    Not enrolling at this site.

  • Adult & Pediatric Urology P.C
    Omaha, Nebraska 68114, United States
    Active, not recruiting

    Not enrolling at this site.

  • Premier Medical Group,
    Poughkeepsie, New York 12603, United States
    Active, not recruiting

    Not enrolling at this site.

  • MetroHealth System,
    Cleveland, Ohio 44109, United States
    Active, not recruiting

    Not enrolling at this site.

  • Women's Healthcare Associates,
    Portland, Oregon 97225, United States
    Active, not recruiting

    Not enrolling at this site.

  • The Institute for Female Pelvic Medicine and Reconstructive Surgery,
    North Wales, Pennsylvania 19454, United States
    Active, not recruiting

    Not enrolling at this site.

  • Southern Urogynecology,
    West Columbia, South Carolina 29169, United States
    Active, not recruiting

    Not enrolling at this site.

  • Urology Austin,
    Austin, Texas 78759, United States
    Recruiting
    • Brian Mazzarella, MD · Contact(502)-569-7904
    • Michelle Valentin-Rivera · Contact(502)-569-7904
  • UCNT Dallas,
    Dallas, Texas 75231, United States
    Active, not recruiting

    Not enrolling at this site.

  • Virginia Mason Medical Center,
    Seattle, Washington 98101, United States
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2029, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Aug 28, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07144813
Lead sponsor
Neuspera Medical, Inc.
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Sep 3, 2025
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Feb 4, 2026

Study contacts

Mark Vollmer
Contact
mark.vollmer@neuspera.com
408-433-3839
Shital Patel
Contact
shital.patel@neuspera.com
323-528-1320
Osvaldo Padron, MD
principal investigator · Florida Urology Partners

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion